中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

73 records (took 0.035 seconds)

    Method and composition of glycosaminoglycans in sickle cell and vascular disorders
    41.
    发明授权
    Method and composition of glycosaminoglycans in sickle cell and vascular disorders 有权
    镰状细胞和血管疾病中糖胺聚糖的方法和组成

    公开(公告)号：US09480703B2

    公开(公告)日：2016-11-01

    申请号：US14526950

    申请日：2014-10-29

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/50 ,  A61K9/14 ,  A61K9/16 ,  A61K31/727 ,  A61K31/737 ,  A61K9/51 ,  A61K47/48 ,  A61K31/00

    CPC classification number: A61K31/737 ,  A61K9/5169 ,  A61K47/6939

    Abstract: A composition that includes a nanoparticle. The nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH). The shell includes poly L-arginine. The SNACH is ionically or covalently bonded to the poly L-arginine. A method for treating a disorder of a subject includes: administering to the subject a therapeutically effective amount of the composition for treating the disorder. The disorder is a vascular disorder, a complication of the vascular disorder, or a combination thereof.

    Abstract translation: 包含纳米颗粒的组合物。 纳米颗粒包括封装硫酸化非抗凝血剂肝素（SNACH）的壳。 壳包括聚L-精氨酸。 SNACH离子或共价键合到聚L-精氨酸。 用于治疗受试者病症的方法包括：向受试者施用治疗有效量的用于治疗病症的组合物。 该疾病是血管疾病，血管疾病的并发症或其组合。

    Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
    44.
    发明授权
    Nanoformulation of vitamin D derivatives and/or vitamin D metabolites 有权
    维生素D衍生物和/或维生素D代谢产物的纳米制剂

    公开(公告)号：US08968790B2

    公开(公告)日：2015-03-03

    申请号：US13706755

    申请日：2012-12-06

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/14 ,  A61K9/16 ,  A61K9/51 ,  A61K47/48 ,  B82Y5/00

    CPC classification number: A61K9/5161 ,  A61K47/48038 ,  A61K47/4823 ,  A61K47/542 ,  A61K47/61 ,  B82Y5/00 ,  Y10S977/773 ,  Y10S977/906

    Abstract: A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder. A nano-cosmetic formulation, comprising a cosmetic includes the nanoformulation, wherein the modified chitosan polymer encapsulates the at least one vitamin D derivative, and wherein the at least one vitamin D derivative encompasses 0.1 to 20.0 wt % of the nano-cosmetic formulation's total weight.

    Abstract translation: 包括负载纳米粒子的纳米制剂。 每个纳米颗粒包括包封至少一种维生素D衍生物，至少一种维生素D代谢物或其组合的改性壳聚糖聚合物。 改性的壳聚糖聚合物包括共价连接到选自脂肪酸（ω-3-脂肪酸），氨基酸，脱氧胆酸，藻酸盐，精氨酸 - 藻酸盐，透明质酸，胶原，胶原 - 羟基磷灰石 ，聚（乳酸 - 共 - 乙醇酸）（PLGA）及其组合。 一种结构包括介质和纳米制剂，其中纳米颗粒分散在介质中。 使用纳米制剂治疗病症并改善当前治疗方法的功效的方法，其中患者的耐药性发展包括向患者施用治疗有效量的用于治疗病症的纳米制剂。 包含化妆品的纳米化妆品制剂包括纳米制剂，其中所述改性的壳聚糖聚合物包封所述至少一种维生素D衍生物，并且其中所述至少一种维生素D衍生物包含纳米化妆品制剂的总重量的0.1至20.0重量％ 。

    Filter composites for drug detoxification
    46.
    发明授权
    Filter composites for drug detoxification 有权
    过滤复合材料用于药物解毒

    公开(公告)号：US08607989B2

    公开(公告)日：2013-12-17

    申请号：US12815453

    申请日：2010-06-15

    Applicant: Shaker A. Mousa ,  Robert J. Linhardt

    Inventor： Shaker A. Mousa ,  Robert J. Linhardt

    IPC: B01D37/00 ,  A61K9/70 ,  A61K31/727 ,  B01D29/00

    CPC classification number: A61L33/0029 ,  A61B17/06166 ,  A61B2017/00526

    Abstract: A filter and a method of forming a suture structure. The filter includes layered structure(s) interior to the filter. Each layered structure includes a carbon structure comprising carbon and a coating on a surface of the carbon structure. Each layered structure may further include a heparin layer that includes heparin and is on the coating. The coating of the filter includes cellulose, PMMA, PEMA, or PHEMA. The carbon structure may include an activated charcoal layer or carbon nanotube(s). The layered structure is configured to remove a contaminant flowing through the filter. The method of forming the suture structure includes forming a film on a suture that has been previously formed on a mammal. The film includes both a coating on the suture and a heparin layer that includes heparin and is on the coating. The coating of the suture structure includes cellulose, PMMA, PEMA, or PHEMA.

    Abstract translation: 一种形成缝线结构的过滤器和方法。 过滤器包括过滤器内部的分层结构。 每个层状结构包括碳结构，其包含碳和碳结构表面上的涂层。 每个层状结构还可以包括包含肝素并且在涂层上的肝素层。 过滤器的涂层包括纤维素，PMMA，PEMA或PHEMA。 碳结构可以包括活性炭层或碳纳米管。 分层结构被配置为去除流过过滤器的污染物。 形成缝线结构的方法包括在预先形成于哺乳动物上的缝线上形成膜。 该膜包括缝合线上的涂层和包含肝素并且在涂层上的肝素层。 缝合结构的涂层包括纤维素，PMMA，PEMA或PHEMA。

    Oxidized heparin fractions and their use in inhibiting angiogenesis
    50.
    发明授权
    Oxidized heparin fractions and their use in inhibiting angiogenesis 有权
    氧化肝素部分及其在抑制血管生成中的应用

    公开(公告)号：US08071569B2

    公开(公告)日：2011-12-06

    申请号：US13029584

    申请日：2011-02-17

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K31/727 ,  C08B37/10 ,  C07H11/00

    CPC classification number: A61K31/727 ,  A61K31/737 ,  A61K45/06 ,  C08B37/0078 ,  A61K2300/00

    Abstract: The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates to methods of inhibiting angiogenesis and treating an angiogenesis-mediated disorder in a subject by administering a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 30,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. Another aspect of the present invention relates to compositions including the heparin fractions of the present invention.

    Abstract translation: 本发明涉及包含分子量为约2,000至约4,000道尔顿的成分的肝素级分，其中约1％至约100％的组分的羟基残基被氧化。 本发明还涉及通过施用包含分子量为约2,000至约30,000道尔顿的组分的肝素级分，其中约1％至约100％的羟基，通过施用抑制血管发生并治疗受试者血管生成介导的病症的方法 组分的残基被氧化。 本发明的另一方面涉及包含本发明的肝素级分的组合物。

Patent Agency Ranking